Visiox Pharma, LLC, a Tarrytown, N.Y.-based biopharmaceutical company focused on the development and commercialization of ophthalmic drugs, closed a $7M seed round of financing.
The round was funded by the Founding Partners and an exclusive group of ophthalmic industry leaders.
The company intends to use the funds to finalize and submit the NDAs for its lead assets, manufacture initial inventory, and add key talent as the company expands its commercial team.
Led by Ryan Bleeks, Chief Executive Officer, Visiox is a biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options.
The company plans to submit two New Drug Applications to the U.S. FDA later this year in the glaucoma and cataract surgery markets. Its lead candidate, PDP-716, is a novel once daily brimonidine formulation utilizing the patented TearAct™ delivery technology, which provides slow, consistent, and sustained release for IOP control throughout the day. SDN-037 is a twice daily topical difluprednate corticosteroid utilizing our patented TJM™ (Tight Junction Modulation) Micellar platform. The novel technology provides post-surgical control of inflammation in a clear solution enabling convenient dosing with a proven active ingredient.